Synthaverse

Synthaverse FCF Margin

The Free Cash Flow Margin of Synthaverse (SVE.WA) as of Oct 17, 2026 is -49.54 %. In the previous year, Free Cash Flow Margin was -39.18 % — a change of 26.45% (lower).

FCF Margin

-49.54 %

YoY

26.45%

Last updated:

Free Cash Flow Margin of Synthaverse is 2025 -49.54 % . Free Cash Flow Margin of Synthaverse was 2024 -39.18 % . It decreases by 26.45% lower compared to the previous year.

The Synthaverse FCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Margin
Date
FCF Margin
Jan 1, 2018
-10.11 PLN
Jan 1, 2019
18.80 PLN
Jan 1, 2020
-4.19 PLN
Jan 1, 2021
-52.75 PLN
Jan 1, 2022
-67.10 PLN
Jan 1, 2023
-201.25 PLN
Jan 1, 2024
-39.18 PLN
Jan 1, 2025
-49.54 PLN
The Synthaverse FCF Margin history
YEARFCF MarginYoY
-49.54 %+26.45%
-39.18 %-80.53%
-201.25 %+199.92%
-67.10 %+27.20%
-52.75 %+1,159.46%
-4.19 %-122.27%
18.80 %-286.05%
-10.11 %-181.98%
12.33 %-58.34%
29.60 %-128.11%
-105.29 %+805.64%
-11.63 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Synthaverse Stock analysis

What does Synthaverse do? Biomed Lublin is a Polish company that has been active in the production of serums and vaccines since 1950. It has grown to become a leading producer of biological substances and medical devices in Eastern Europe. The company was originally a state institution for the development of animal vaccines but was privatized after the political changes in the late 1980s. Since 2002, it has been listed on the Warsaw Stock Exchange and has expanded its focus. Biomed Lublin operates in four main areas: veterinary medicine, human medicine, diagnostics, and laboratory equipment. It has a strong reputation in the veterinary medicine field, offering vaccines and diagnostics for livestock and pets. The company is also involved in human medicine, producing vaccines and diagnostics exclusively in Poland. In the diagnostics field, Biomed Lublin has developed and manufactured a variety of test kits used in medical diagnostics. It also offers laboratory equipment such as microscopes, pipettes, and centrifuges for medical and biological testing in hospitals and laboratories. Overall, Biomed Lublin aims to continue expanding its presence in the biotech industry in Eastern Europe and providing high-quality and effective diagnostic and therapeutic solutions to improve the health of both humans and animals. Synthaverse is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Synthaverse stock

Free Cash Flow Margin of Synthaverse is -49.54 % in 2025.

Free Cash Flow Margin of Synthaverse changed from -39.18 % to -49.54 %, representing a 26.45% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Margin Synthaverse since 2006 – with annual values, charts, and detailed analysis.

FCF Margin measures the percentage of revenue converted to free cash flow. It indicates how efficiently a company generates cash from its operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Margin's Synthaverse with sector peers and the industry average to assess whether it is attractive.

To evaluate Free Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Synthaverse

All Key Metrics — Synthaverse